Predictive Biomedicine and Translational Research in Respiratory, Cardiovascular, and Metabolic Diseases

Strategic objectives

  • To encourage and facilitate basic-clinical translational research in respiratory, cardiovascular, and metabolic diseases.
  • To identify biomarkers and clinical predictors related to the prevention, prognosis, and treatment efficacy of respiratory, cardiovascular, and metabolic diseases.
  • To study the efficacy of new drugs in respiratory, cardiovascular, and metabolic diseases. To identify biomarkers and molecular signalling pathways related to drug response in cells.
  • To promote quality care and innovation in the clinical management of respiratory, cardiovascular, and metabolic diseases.
  • To promote the creation of national registers of rare respiratory diseases.
  • To study genes and genetic polymorphisms associated with nutrition and physical exercise potentially related to the risk of respiratory, cardiovascular, and metabolic diseases.
  • To study mechanisms associated with cellular senescence.
  • One of the main strategic objectives of the group is also training and teaching through doctoral theses and the publication of scientific and informative books.

Lines of research

  • Development of predictive algorithms using artificial intelligence based on genetic and protein biomarkers to predict overweight/obesity, its comorbidities and ageing.
  • Search for biomarkers and clinical predictors of prognosis and/or adherence to secondary and tertiary prevention systems for cardiovascular, respiratory, and metabolic diseases based on secondary sources.
  • Study of molecular mechanisms associated with the development and progression of abdominal aortic aneurysm and varicose veins, and the action of drugs.
  • Mechanisms related to pathological alterations of the auditory system.
  • Analysis of the mechanisms associated with the response of platelets and their surrounding cells to antithrombotic and anticoagulant treatments. COVID-19 effects on the vascular wall.
  • Study of biomarkers modifying alpha-1 antitrypsin deficiency.
  • Development of a non-invasive smart medical device for the treatment of sleep apnoea syndrome.
  • Evaluative analysis of quality standards in chronic obstructive pulmonary disease care.
  • Study of clinical predictors for establishing lifestyle changes in chronic obstructive pulmonary disease.
  • Study of the effectiveness of inhaled antibiotic therapy in chronic obstructive pulmonary disease.

Other members of the group

  • José Luis Álvarez-Sala Walther
  • Maria Jose Bernabe Barrios
  • Manuel Gómez Serrano
  • Miriam Garcia Carro
  • Mª Cruz Iglesias Moreno
  • Vicente Lahera Juliá
  • Ana Lopez De Andres
  • María Teresa Marín Becerra
  • Antonio Ignacio Martín Conejero
  • Carlos Hugo Martínez Martínez
  • Guillermo Moñux Ducajú
  • Joaquín Poch Broto
  • David Rodríguez Calle
  • Juan Luis Rodriguez Hermosa
  • Francisco Javier Serrano Hernando
  • Gianna Vargas Centanaro
  • Khaoula Zekri

Publications

Projects